Pharma Giants Shift to Small Bolt-On Acquisitions Over Mega-Mergers

Major pharmaceutical companies are shifting their merger and acquisition strategies away from massive, multi-billion dollar deals toward a steady stream of smaller, targeted bolt-on acquisitions. This trend is driven by investor skepticism following failed large-scale mergers, such as the $74 billion acquisition of Celgene by Bristol Myers Squibb, which failed to deliver positive shareholder returns.

Eli Lilly and Company and Novartis are utilizing this disciplined approach to diversify their pipelines before facing patent cliffs, where protections for blockbuster drugs expire. Novartis has narrowed its ambitions toward smaller bets, including a $12 billion deal for Avidity Biosciences. Eli Lilly has executed numerous targeted deals in 2026 across gene editing, sleep, cancer, and psychedelics.

Merck is similarly avoiding a single overwhelming acquisition to replace revenue from its cancer drug Keytruda, which loses protection in 2028, opting instead for targeted assets and partnerships. Market reactions continue to reinforce this preference for lower-risk bets; AstraZeneca shares recently plunged following reports that the company explored a merger with Bristol Myers Squibb.